...
bgne-img

BeiGene Ltd, Common Stock

BGNE

NSQ

$175.113

-$3.95

(-2.21%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$19.97B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
466.11K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.63
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$126.97 L
$248.16 H
$175.113

About BeiGene Ltd, Common Stock

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. The company's clinical stage products comprise BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; BGB-10188; BGB-21447, a Bcl-2 inhibitor; Ociperlimab (BGB-A1217), a TIGIT inhibitor; Zanidatamab, a bispecific HER2-targeted antibody; Surzebiclimab (BGB-A425), a TIM-3 inhibitor; BGB-A445, an OX40 agonist antibody; BGB-15025, a small molecule inhibitor of HPK1; BGB-24714, a SMAC mimetic; BGB-26808, a HPK-1 inhibitor; Lifirafenib and BGB-3245 that are inhibitors of RAF; BGB-30813; BGB-A3055, an anti-CCR8 antibody; and BGB-43395, a CDK-4 inhibitor. It also has various preclinical programs. The company has license agreements with Ensem Therapeutics, Inc.; Shandong Luye Pharmaceutical Co., Ltd.; Shoreline Biosciences, Inc.; Nanjing Leads Biolabs, Inc.; EUSA Pharma; Assembly Biosciences, Inc.; Bio-Thera Solutions, Ltd.; Amgen Inc.; and Beijing Novartis Pharma Co., Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameBGNESectorS&P500
1-Week Return-4.5%-3.39%0.2%
1-Month Return-4.6%-1.92%2.72%
3-Month Return-9.34%-10.54%7.31%
6-Month Return12.35%-4.47%10.44%
1-Year Return-1.86%4.06%27.53%
3-Year Return-34.58%0.94%30.88%
5-Year Return9.95%36.67%89.21%
10-Year Return532.27%102.87%199.95%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue428.21M308.87M1.18B1.42B2.46B[{"date":"2019-12-31","value":17.42,"profit":true},{"date":"2020-12-31","value":12.56,"profit":true},{"date":"2021-12-31","value":47.84,"profit":true},{"date":"2022-12-31","value":57.59,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue998.53M1.37B1.62B1.93B379.92M[{"date":"2019-12-31","value":51.82,"profit":true},{"date":"2020-12-31","value":70.86,"profit":true},{"date":"2021-12-31","value":84.28,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":19.72,"profit":true}]
Gross Profit(570.32M)(1.06B)(447.86M)(511.06M)2.08B[{"date":"2019-12-31","value":-27.43,"profit":false},{"date":"2020-12-31","value":-50.83,"profit":false},{"date":"2021-12-31","value":-21.54,"profit":false},{"date":"2022-12-31","value":-24.58,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin(133.19%)(342.10%)(38.07%)(36.09%)84.55%[{"date":"2019-12-31","value":-157.53,"profit":false},{"date":"2020-12-31","value":-404.62,"profit":false},{"date":"2021-12-31","value":-45.03,"profit":false},{"date":"2022-12-31","value":-42.69,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Operating Expenses389.57M601.02M990.87M1.28B3.29B[{"date":"2019-12-31","value":11.85,"profit":true},{"date":"2020-12-31","value":18.29,"profit":true},{"date":"2021-12-31","value":30.15,"profit":true},{"date":"2022-12-31","value":38.9,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(959.89M)(1.66B)(1.44B)(1.79B)(1.21B)[{"date":"2019-12-31","value":-95989100000,"profit":false},{"date":"2020-12-31","value":-165768200000,"profit":false},{"date":"2021-12-31","value":-143873500000,"profit":false},{"date":"2022-12-31","value":-178966500000,"profit":false},{"date":"2023-12-31","value":-120773600000,"profit":false}]
Total Non-Operating Income/Expense25.44M41.49M(15.61M)(118.89M)457.85M[{"date":"2019-12-31","value":5.56,"profit":true},{"date":"2020-12-31","value":9.06,"profit":true},{"date":"2021-12-31","value":-3.41,"profit":false},{"date":"2022-12-31","value":-25.97,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(943.59M)(1.62B)(1.44B)(1.96B)(825.84M)[{"date":"2019-12-31","value":-94358600000,"profit":false},{"date":"2020-12-31","value":-161819400000,"profit":false},{"date":"2021-12-31","value":-143858800000,"profit":false},{"date":"2022-12-31","value":-196103700000,"profit":false},{"date":"2023-12-31","value":-82583600000,"profit":false}]
Income Taxes6.99M(17.67M)(25.23M)42.78M55.87M[{"date":"2019-12-31","value":12.51,"profit":true},{"date":"2020-12-31","value":-31.63,"profit":false},{"date":"2021-12-31","value":-45.16,"profit":false},{"date":"2022-12-31","value":76.56,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes(950.58M)(1.60B)(1.41B)(2.00B)(881.71M)[{"date":"2019-12-31","value":-95057800000,"profit":false},{"date":"2020-12-31","value":-160052300000,"profit":false},{"date":"2021-12-31","value":-141335400000,"profit":false},{"date":"2022-12-31","value":-200381500000,"profit":false},{"date":"2023-12-31","value":-88170800000,"profit":false}]
Income From Continuous Operations(950.58M)(1.60B)(1.41B)(2.00B)(959.49M)[{"date":"2019-12-31","value":-95057800000,"profit":false},{"date":"2020-12-31","value":-160052300000,"profit":false},{"date":"2021-12-31","value":-141335400000,"profit":false},{"date":"2022-12-31","value":-200381500000,"profit":false},{"date":"2023-12-31","value":-95949000000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(950.58M)(1.60B)(1.41B)(2.00B)(881.71M)[{"date":"2019-12-31","value":-95057800000,"profit":false},{"date":"2020-12-31","value":-160052300000,"profit":false},{"date":"2021-12-31","value":-141335400000,"profit":false},{"date":"2022-12-31","value":-200381500000,"profit":false},{"date":"2023-12-31","value":-88170800000,"profit":false}]
EPS (Diluted)(15.74)(19.02)(15.16)(19.51)(11.71)[{"date":"2019-12-31","value":-1574,"profit":false},{"date":"2020-12-31","value":-1902,"profit":false},{"date":"2021-12-31","value":-1516,"profit":false},{"date":"2022-12-31","value":-1951,"profit":false},{"date":"2023-12-31","value":-1171,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

BGNE
Cash Ratio 1.33
Current Ratio 1.93
Quick Ratio 1.72

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

BGNE
ROA (LTM) -9.58%
ROE (LTM) -23.22%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

BGNE
Debt Ratio Lower is generally better. Negative is bad. 0.41
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.59

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

BGNE
Trailing PE NM
Forward PE 384.62
P/S (TTM) 0.85
P/B 5.55
Price/FCF 365
EV/R 5.54
EV/Ebitda NM
PEG NM

FAQs

What is BeiGene Ltd share price today?

BeiGene Ltd (BGNE) share price today is $175.113

Can Indians buy BeiGene Ltd shares?

Yes, Indians can buy shares of BeiGene Ltd (BGNE) on Vested. To buy BeiGene Ltd from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in BGNE stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of BeiGene Ltd be purchased?

Yes, you can purchase fractional shares of BeiGene Ltd (BGNE) via the Vested app. You can start investing in BeiGene Ltd (BGNE) with a minimum investment of $1.

How to invest in BeiGene Ltd shares from India?

You can invest in shares of BeiGene Ltd (BGNE) via Vested in three simple steps:

  • Click on Sign Up or Invest in BGNE stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in BeiGene Ltd shares
What is BeiGene Ltd 52-week high and low stock price?

The 52-week high price of BeiGene Ltd (BGNE) is $248.16. The 52-week low price of BeiGene Ltd (BGNE) is $126.97.

What is BeiGene Ltd price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of BeiGene Ltd (BGNE) is

What is BeiGene Ltd price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of BeiGene Ltd (BGNE) is 5.55

What is BeiGene Ltd dividend yield?

The dividend yield of BeiGene Ltd (BGNE) is 0.00%

What is the Market Cap of BeiGene Ltd?

The market capitalization of BeiGene Ltd (BGNE) is $19.97B

What is BeiGene Ltd’s stock symbol?

The stock symbol (or ticker) of BeiGene Ltd is BGNE

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top